Guido Papa

Dr. Guido Papa

Department of Biomedical Sciences, University of Milan, Milan, Lombardy, Italy
orcid
Group Leader at the University of Milan, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Guido PapaGuido Papa
Guido Papa
DMDonna L. Mallery
Donna L. Mallery
AAAnna Albecka
Anna Albecka
LWLawrence G. Welch
Lawrence G. Welch
JCJérôme Cattin-Ortolá
Jérôme Cattin-Ortolá
LJLeo James
Leo James
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infects cells by binding to the host cell receptor ACE2 and undergoing virus-host membrane fusion. Fusion is triggered by the protease TMPRSS2, which processes the viral Spike (S) protein to reveal the fusion peptide. SARS-CoV-2 has evolved a multibasic site at the S1-S2 boundary, which is thought to be cleaved by furin in order to prime S protein for TMPRSS2 processing. Here we show that CRISPR-Cas9 knockout of furin reduces, but does not prevent, the production of infectious SARS-CoV-2 virus. Comparing S processing in furin knockout cells to multibasic site mutants reveals that while loss of furin substantially reduces S1-S2 cleavage it does not prevent it. SARS-CoV-2 S protein also mediates cell-cell fusion, potentially allowing virus to spread virion-independently. We show that loss of furin in either donor or acceptor cells reduces, but does not prevent, TMPRSS2-dependent cell-cell fusion, unlike mutation of the multibasic site that completely prevents syncytia formation. Our results show that while furin promotes both SARS-CoV-2 infectivity and cell-cell spread it is not essential, suggesting furin inhibitors may reduce but not abolish viral spread.

15 September 2021 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
FGFlorian Geiger
Florian Geiger
JAJulia Acker
Julia Acker
Guido PapaGuido Papa
Guido Papa
XWXinyu Wang
Xinyu Wang
WAWilliam E Arter
William E Arter
ABAlexander Borodavka
Alexander Borodavka
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

12 July 2021 in Viruses
Verified
Journal Article
Open access
PDF file
Guido PapaGuido Papa
Guido Papa
ABAlexander Borodavka
Alexander Borodavka
Ulrich DesselbergerUlrich Desselberger
Ulrich Desselberger
Viroplasms are cytoplasmic, membraneless structures assembled in rotavirus (RV)-infected cells, which are intricately involved in viral replication. Two virus-encoded, non-structural proteins, NSP2 and NSP5, are the main drivers of viroplasm formation. The structures (as far as is known) and functions of these proteins are described. Recent studies using plasmid-only-based reverse genetics have significantly contributed to elucidation of the crucial roles of these proteins in RV replication. Thus, it has been recognized that viroplasms resemble liquid-like protein–RNA condensates that may be formed via liquid–liquid phase separation (LLPS) of NSP2 and NSP5 at the early stages of infection. Interactions between the RNA chaperone NSP2 and the multivalent, intrinsically disordered protein NSP5 result in their condensation (protein droplet formation), which plays a central role in viroplasm assembly. These droplets may provide a unique molecular environment for the establishment of inter-molecular contacts between the RV (+)ssRNA transcripts, followed by their assortment and equimolar packaging. Future efforts to improve our understanding of RV replication and genome assortment in viroplasms should focus on their complex molecular composition, which changes dynamically throughout the RV replication cycle, to support distinct stages of virion assembly.

1 December 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SCSarah Caddy
Sarah Caddy
MVMarina Vaysburd
Marina Vaysburd
Guido PapaGuido Papa
Guido Papa
MWMark Wing
Mark Wing
KOKevin O’COnnell
Kevin O’COnnell
LJLeo James
Leo James
Nucleoprotein (N) is an immunodominant antigen in many enveloped virus infections. While the diagnostic value of anti‐N antibodies is clear, their role in immunity is not. This is because while they are non‐neutralising, they somehow clear infection by coronavirus, influenza and LCMV in vivo . Here, we show that anti‐N immune protection is mediated by the cytosolic Fc receptor and E3 ubiquitin ligase TRIM21. Exploiting LCMV as a model system, we demonstrate that TRIM21 uses anti‐N antibodies to target N for cytosolic degradation and generate cytotoxic T cells (CTLs) against N peptide. These CTLs rapidly eliminate N‐peptide‐displaying cells and drive efficient viral clearance. These results reveal a new mechanism of immune synergy between antibodies and T cells and highlights N as an important vaccine target.

1 October 2021 in Virus Research
Verified
Journal Article
Closed access
SCSarah Caddy
Sarah Caddy
Guido PapaGuido Papa
Guido Papa
ABAlexander Borodavka
Alexander Borodavka
Ulrich DesselbergerUlrich Desselberger
Ulrich Desselberger

13 September 2024 in Cell
Verified
Journal Article
Open access
LMLauren V.C. Miller
Lauren V.C. Miller
Guido PapaGuido Papa
Guido Papa
MVMarina Vaysburd
Marina Vaysburd
SCShi Cheng
Shi Cheng
PSPaul W. Sweeney
Paul W. Sweeney
LJLeo James
Leo James
Protein aggregation causes a wide range of neurodegenerative diseases. Targeting and removing aggregates, but not the functional protein, is a considerable therapeutic challenge. Here, we describe a therapeutic strategy called "RING-Bait," which employs an aggregating protein sequence combined with an E3 ubiquitin ligase. RING-Bait is recruited into aggregates, whereupon clustering dimerizes the RING domain and activates its E3 function, resulting in the degradation of the aggregate complex. We exemplify this concept by demonstrating the specific degradation of tau aggregates while sparing soluble tau. Unlike immunotherapy, RING-Bait is effective against both seeded and cell-autonomous aggregation. RING-Bait removed tau aggregates seeded from Alzheimer's disease (AD) and progressive supranuclear palsy (PSP) brain extracts and was also effective in primary neurons. We used a brain-penetrant adeno-associated virus (AAV) to treat P301S tau transgenic mice, reducing tau pathology and improving motor function. A RING-Bait strategy could be applied to other neurodegenerative proteinopathies by replacing the Bait sequence to match the target aggregate.